GlassScriptPhysician profile
Ann Aleman-Weinmann
NPI 1982660338
$17,517.43
in general payments reported to CMS, 2019-2025
43 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,857 · 2020: $1,693 · 2021: $2,297 · 2022: $2,636 · 2023: $2,929 · 2024: $2,375 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,866 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,865.71 |
| Education | $169.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,958.97 | 2019-2025 | Otezla, Enbrel, Evenity |
| Abbvie INC. | $1,907.51 | 2019-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $1,242.63 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $1,123.35 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $897.22 | 2019-2025 | Orencia |
| Lilly USA, LLC | $834.13 | 2019-2025 | Taltz, Jardiance, Mounjaro |
| Horizon Therapeutics Plc | $747.34 | 2019-2022 | |
| Radius Health, INC. | $625.05 | 2019-2025 | Tymlos |
| Pfizer INC. | $591.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $578.97 | 2019-2025 | |
| Ucb, INC. | $558.23 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $385.11 | 2020-2025 | Benlysta |
| Genentech USA, INC. | $310.46 | 2019-2024 | Actemra, Rituxan |
| Novo Nordisk INC | $265.00 | 2019-2023 | Wegovy |
| Mallinckrodt Hospital Products INC. | $230.33 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $205.16 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $199.19 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $198.63 | 2021-2025 | Lupkynis |
| Janssen Scientific Affairs, LLC | $186.63 | 2023-2025 | Tremfya |
| Celgene Corporation | $161.68 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $150.00 | 2024 | Tremfya |
| Ani Pharmaceuticals, INC. | $145.76 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.68 | 2021-2024 | Cyltezo, Spevigo |
| Organon LLC | $109.64 | 2023-2025 | Hadlima |
| Merck Sharp & Dohme LLC | $88.49 | 2020-2023 | Belsomra, Steglujan, Steglatro |
| Allergan, INC. | $87.12 | 2019 | |
| Nevro Corp. | $71.56 | 2022-2024 | Senza |
| Sandoz INC. | $63.25 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $59.58 | 2023-2024 | Idacio |
| Eisai INC. | $55.89 | 2019-2021 | |
| Exact Sciences Corporation | $54.60 | 2024-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $47.26 | 2023-2024 | Truxima, Simlandi |
| Octapharma USA, INC. | $39.54 | 2022-2025 | Octagam Immune Globulin (Human) |
| Actelion Pharmaceuticals US, INC. | $30.35 | 2019 | |
| Bioventus LLC | $27.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.56 | 2022 | |
| Invivyd INC | $23.00 | 2025 | Pemgarda |
| Sun Pharmaceutical Industries INC. | $21.62 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.12 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $20.34 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.46 | 2025 | Strensiq |
| Gilead Sciences, INC. | $16.46 | 2020 | |
| Henry Schein, INC. | $14.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Aleman-Weinmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.